Role of anidulafungin in critically ill patients;Papel de anidulafungina en el paciente crítico

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 14, 2008, Pages 35-43

  Borges Sá, Márcio ^a   Garnacho Montero, José ^b  

^a HOSPITAL SON LLÀTZER   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Empirical and preemptive antifungal therapy; Invasive candidiasis

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE; AMPHOTERICIN B; ANTIFUNGAL AGENT; ECHINOCANDIN;

ANTIBIOTIC THERAPY; CANDIDA ALBICANS; CANDIDEMIA; CRITICAL ILLNESS; DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; HUMAN; IMMUNOCOMPETENCE; INCIDENCE; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; NEPHROTOXICITY; RELIABILITY; REVIEW; RISK FACTOR; SCORING SYSTEM; CANDIDIASIS; CLINICAL TRIAL; CROSS INFECTION; DRUG COMBINATION; FUNGEMIA; MICROBIOLOGY; PRACTICE GUIDELINE; STATISTICS;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDIASIS; CLINICAL TRIALS AS TOPIC; CRITICAL ILLNESS; CROSS INFECTION; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FLUCONAZOLE; FUNGEMIA; HUMANS; IMMUNOCOMPETENCE; INTENSIVE CARE UNITS; ITRACONAZOLE; PRACTICE GUIDELINES AS TOPIC;

EID: 69249231153     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(08)76591-1     Document Type: Article

References (67)

1. M. Cuenca Estrella, E. Martin Mazuelos, F. Alvarez Lerma, C. Ortiz Leyba, and C. León Gil Infecciones por Candida spp. en el paciente crítico Med Intensiva 3 2005 S12 S20
2. J.L. Rodríguez-Tudela, and M. Cuenca-Estrella Candidosis sistémicas o profundas P. Farreras C. Rozman Medicina Interna 2004 Elsevier Madrid 2399 2401
3. M. Nucci, and E. Anaissie Revisting the source of candidemia: Skin or gut? Clin Infect Dis 33 2001 1959 1967 (Pubitemid 33152388)
4. R.A. Hajjeh, A.N. Sofair, L.H. Harrison, M. Lyon, B. Arthington-Skaggs, and S.A. Mirza Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program J Clin Microbiol 42 2004 1519 1527 (Pubitemid 38500790)
5. B. Almirante, D. Rodríguez, B.J. Park, M. Cuenca-Estrella, A.M. Planes, and M. Almela Epidemiology and predictors of mortality in Candida bloodstream infections: results from population-based surveillance, Barcelona, Spain, 2002-2003 J Clin Microbiol 43 2005 1829 1835 (Pubitemid 40491227)
6. O. Marchetti, J. Bille, U. Fluckiger, P. Eggimannn, C. Ruef, and J. Garbino Epidemiology of candidemia in swiss tertiary care hospitals. Secular trends, 1991-2000 Clin Infect Dis 38 2004 311 320 (Pubitemid 38200105)
7. J. Nolla Salas, A. Rodríguez, P. Olaechea Astigarraga, et al. Epidemiología de la infección fúngica en el paciente crítico no granulocitopénico Med Intensiva 3 2005 S4 S11
8. A.N. Sofair, G.M. Marshall Lyon, S. Huie-White, E. Reiss, L. Harrison, and L.T. Sanza Epidemiology of community-onset candidemia in Connecticut and Maryland Clin Infect Dis 43 2006 32 39 (Pubitemid 43939073)
9. P. Eggimann, J. Garbino, and D. Pittet Epidemiology of Candida species infections in critically ill-nonimmunosuppressed patients Lancet Infect Dis 3 2003 685 702 (Pubitemid 37345347)
10. P.E. Charles, J.M. Doise, and J.P. Quenot Candidemia in critically ill patients: difference of outcome between medical and surgical patients Intensive Care Med 29 2003 2162 2169 (Pubitemid 38030666)
11. J. Peman, E. Canton, and M. Gobernado Epidemiology and antifungal susceptibilities of Candida species isolated from blood: results of a 2-year multicentre study in Spain Eur J Clin Microbiol Infect Dis 24 2005 23 30 (Pubitemid 40179128)
12. M.A. Pfaller, and D.J. Diekema Epidemiology of invasive candidiasis: a persistent public health problem Clin Microbiol Rev 20 2007 133 163
13. F.C. Odds, M.F. Hanson, A.D. Davidson, M.D. Jacobsen, P. Wright, and J.A. Whyte One year prospective survey of Candida bloodstream infections in Scotland J Med Microbiol 56 2007 1066 1075 (Pubitemid 47262669)
14. J. Garnacho, C. León, B. Almirante, F. Álvarez, M. Cuenca, J.A. García, et al. Recomendaciones terapéuticas en el paciente crítico no neutropénico. Conferencia de consenso. Conclusiones Med Intensiva 3 2005 S43 S52
15. L. Ostrosky-Zeichner, and P.G. Pappas Invasive candidiasis in the intensive care unit Crit Care Med 34 2006 857 863 (Pubitemid 43308281)
16. R. Jordà-Marcos, F. Álvarez-Lerma, M. Jurado, et al. Risk factors for candidaemia in critically ill patients: a prospective surveillance study Mycoses 50 2007 302 310
17. L. Saiman, E. Ludington, M. Pfaller, S. Rangel-Frausto, R.T. Wiblin, and J. Dawson Risk factors for candidemia in neonatal intensive care unit patients Pediatr Infect Dis J 19 2000 319 324 (Pubitemid 30213071)
18. M. Nucci, and Al. Colombo Candidemia due to Candida tropicalis: clinical, epidemiologic, and microbiologic characteristics of 188 episodes occurring in tertiary care hospitals Diagn Microbiol Infect Dis 58 2007 77 82 (Pubitemid 46694266)
19. B. Almirante, D. Rodríguez, and M. Cuenca-Estrella Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003 J Clin Microbiol 44 2006 1681 1685 (Pubitemid 43726255)
20. M. Winberger, L. Leibovici, S. Perez, E. Samra, I. Ostfeld, and I. Levi Characteristics of candidaemia with Candida albicans compared with non-albicans Candida species and predictors of mortality J Hosp Infect 61 2005 146 154 (Pubitemid 41283339)
21. S.L. Davis, J.A. Vazquez, and P.S. Mckinnan Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients Ann Pharmacother 41 2007 568 573 (Pubitemid 46625479)
22. P. Muñoz, M. Sanchez Somolinos, L. Alcala, M. Rodríguez- Creixems, T. Pelaez, and E. Bouza Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital J Antimictob Chemother 55 2005 188 193 (Pubitemid 40331144)
23. A.F. Shorr, D.R. Lazarus, J.H. Sherner, W.L. Jackson, M. Morrel, and V.S. Fraser Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia Crit Care Med 35 2007 1077 1083 (Pubitemid 46598958)
24. S. Rigby, G.W. Procop, G. Haase, D. Wilson, G. Hall, and Kurtzman Fluorescence in situ hybridization with peptide nucleic acid probes for rapid identification of Candida albicans directly from blood culture bottles J Clin Microbiol 40 2002 2182 2186 (Pubitemid 34596404)
25. Z. Odabasi, G. Mattiuzzi, E. Estey, H. Kantarjian, F. Saeki, and R.J. Ridge Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome Clin Infect Dis 39 2004 199 205 (Pubitemid 38971490)
26. L. Ostrosky-Zeichner, B.D. Alexander, D.H. Kett, J. Vazquez, P.G. Pappas, and F. Saeki Multicenter clinical evaluation of the (1,3) b-d-glucan assay as an aid to diagnosis of fungal infections in humans Clin Infect Dis 41 2005 654 659 (Pubitemid 41170353)
27. S. Ruiz-Santana, C. Castro, P. Saavedra, et al. The Cava Project: (1,3)-β-Dglucan and Candida score in discriminating between colonization and invasive candidiasis non-neutropenic critically ill patients 47th ICAAC Chicago, M-1167 2007 442
28. P.G. Pappas, J.H. Rex, J.D. Sobel, S.G. Filler, W.E. Dismukes, T.J. Walsh, et al. Guidelines for treatment of candidiasis Clin Infect Dis 38 2004 161 189
29. P. Muñoz, A. Burillo, and E. Bouza Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit Int J Antimicrob Agents 15 2000 83 90 (Pubitemid 30347248)
30. C. León, J. Rello, S. Ruiz-Santana, D. León, and M. Marín Planteamiento terapéutico antifúngico empírico en pacientes críticos Med Intensiva Supl 5 2007 21 29
31. M. Borges, and R. Morales Peritonitis grave y uso de antifúngicos: profilaxis, terapia empírica y anticipada. ¿Qué debemos hacer? Med Intensiva Supl 4 2006 29 37
32. a ed. 2006 Silva Tarragona
33. J. Garnacho-Montero, J.L. Garcia-Garmendia, A. Barrero-Almodovar, F.S. Jiménez-Jiménez, C. Pérez-Paredes, and C. Ortiz-Leyba Impact of adequate empirical antibiotic therapy on the oytcome of patients admitted to the intensive care unit with sepsis Crit Care Med 31 2003 2742 2751 (Pubitemid 38010630)
34. M. Morrell, V.J. Fraser, and M.J. Kollef Delaying empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for mortality Antimicrob Agents Chemother 49 2005 3640 3645 (Pubitemid 41233011)
35. P. Eggimann, J. Garbino, and D. Pittet Management of Candida species infections in critically ill patients Lancet Infect Dis 3 2003 772 785 (Pubitemid 37489961)
36. J. Solomkin, J. Mazuski, E. Baron, R. Sawer, A. Nathens, J. DiPiro, and T. Buchman Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections Clin Infect Dis 37 2003 997 1005 (Pubitemid 37323652)
37. J.M. Tellado, A. Sitges-Sierra, F. Barcenilla, M. Palomar, R. Serrano, and J. Barberán Pautas de tratamiento antibiótico empírico de las infecciones intraabdominales Rev Esp Quimioterap 18 2005 179 186 (Pubitemid 41059895)
38. R. Zaragoza, and F. Mariscal Tratamiento de la candidiasis en enfermos críticos no neutropenicos: papel de la anfotericina lipídica Med Intensiva 5 2007 38 48
39. T.G. Gleason, A.K. May, D. Caparelli, B.M. Farr, R.G. Sawyer, and J.S. Solomkin Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units Arch Surg 132 1997 1197 1202 (Pubitemid 27486048)
40. D. Pittet, M. Monod, P.M. Suter, E. Frenk, and R. Auckenthaler Candida colonization and subsequent infections in critically ill surgical patients Ann Surg 220 1994 751 758 (Pubitemid 24376373)
41. H. Dupont, A. Bourichon, C. Paugam-Burtz, J. Mantz, and J.M. Desmonts Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med 31 2003 752 757 (Pubitemid 36379578)
42. C. León, S. Ruiz-Santana, P. Saavedra, B. Almirante, J. Nolla-Salas, and F. Álvarez-Lerma A bedside scoring system («Candida score») for early antifungal treatment in non-neutropenic critically ill patients with Candida colonization Crit Care Med 34 2006 730 737 (Pubitemid 43308263)
43. S. Ruiz-Santana, C. León, P. Saavedra, B. Galvan, A. Utande, M. Blasco, et al; Cava Study Group Validation study of the Candida score for discriminating between colonization an invasive candidiasis in non-neutropenic critically ill patients. [resumen M-1167] 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 2007 Chicago 2007
44. H.M. Blumberg, W.R. Jarvis, J.M. Soucie, J.E. Edwards, J.E. Patterson, M.A. Pfaller, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey Clin Infect Dis 33 2001 177 186
45. R. Piarroux, F. Grenouillet, P. Balvay, V. Tran, G. Blasco, and L. Millon Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients Crit Care Med 32 2004 2443 2449 (Pubitemid 39648226)
46. S.I. Blot, K.H. Vandewoude, E.A. Hoste, and F.A. Colardyn Effects of nosocomial candidemia on outcomes of critically ill patients Am J Med 113 2002 480 485 (Pubitemid 35335800)
47. B.J. Kullberg, J.D. Sobel, M. Ruhnke, P.G. Pappas, C. Viscoli, and J.H. Rex Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial Lancet 366 2005 1435 1442 (Pubitemid 41483809)
48. R. Zaragoza Crespo, and P. Luque Gómez Voriconazol en UCI: ¿Cuáles son sus indicaciones, ventajas, precauciones y contraindicaciones reales? Med Intensiva 4 2006 S11 S18
49. J. Pemán, M. Salavert, E. Cantón, I. Jarque, E. Roma, and R. Zaragoza Voriconazole in the management of nosocomial invasive fungal infections Ther Clin Risk Manage 2 2006 1 30 (Pubitemid 43950051)
50. F. Alvarez-Lerma, J.M. Nicolas-Arfelis, J.C. Rodriguez-Borregan, J. Díaz-Regañón, M. Sa-Borges, and F. García- López Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients J Chemother 17 2005 417 427 (Pubitemid 41284781)
51. R. Herbrecht, D.W. Denning, T.F. Patterson, J.E. Bennett, R.E. Greene, and J.O. Oestmann Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med 347 2002 408 415 (Pubitemid 34851833)
52. J. Mora-Duarte, R. Betts, C. Rotstein, A. López Colombo, L. Thompson-Moya, and J. Smietama Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 2002 2020 2029 (Pubitemid 35461658)
53. E.R. Kuse, P. Chetchotisakd, C.A. Da Cunha, M. Ruhnke, C. Barrios, D. Raghunadharao Micafungin Invasive Candidiasis Working Group Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial Lancet 369 2007 1519 1527 (Pubitemid 46670281)
54. A.C. Reboli, C. Rotstein, P.G. Pappas, S.W. Chapman, D.H. Kett, D. Kumar Anidulafungin Study Group Anidulafungin versus fluconazole for invasive candidiasis N Engl J Med 356 2007 2472 2482 (Pubitemid 46919773)
55. H. Boucher, A. Groll, C. Chiou, and T. Walsh Newer systemic antifungal agents Drugs 64 2004 1997 2020
56. J.A. Vazquez, and J.D. Sobel Anidulafungin: a novel echinocandin Clin Infect Dis 43 2006 215 222
57. J.A. Vazquez Anidulafungin: a novel echicandin Therapy 3 2006 39 54
58. D. Murdoch, and G. Plosker Anidulafungin Drugs 64 2004 2249 2258 (Pubitemid 39382216)
59. J. Vehreschild, T. Kümmerle, M. Karthaus, and O. Cornely Anidulafungin - state of affaire from a clinical perspective Mycosis 50 2007 38 43 (Pubitemid 46495989)
60. M. Cohen-Wolkowiez, D. Benjamín, W. Steinbach, and P. Smith Drugs of today 42 2006 533 544
61. P. Torre, and A. Reboli Anidulafungin: a new echicandin for candidal infections Expert Rev Anti Infect Ther 5 2007 45 52 (Pubitemid 46613386)
62. C. Acuña Anidulafungina. Actualización microbiológica y clínica Drugs of today 2 2008 3 25
63. M. Borges, and J. Pemán Tratamiento antifúngico combinado en pacientes críticos: perspectivas futuras Med. Intensiva Supl 5 2007 30 37
64. N. Singh, A.P. Limaye, G. Forrest, N. Safdar, P. Muñoz, and K. Pursell Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study Transplantation 81 2006 320 326 (Pubitemid 43255714)
65. K. Marr Combination antifungal therapy: where are we now, and where are we going? Oncology (Williston Park) 18 Suppl 7 2004 24 29
66. R. Zaragoza, and J. Pemán Diagnostic and therapeutic approach to fungal infections in critical care settings: different options but the same strategy J Invasive Fungal Infect 1 2007 50 58
67. P.G. Pappas Treatment of candidiasis. Update on fangal fungal treatment guidelines. Infections Diseases Society of America (IDSA) 45th Annual Meeting 2007 October